Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test

Lundbeck’s 5-HT6 antagonist idalopirdine failed its first Phase III test, but as Axovant awaits data from its Phase III study for a competing Alzheimer’s therapy, it’s still unclear whether the entire drug class is doomed to the same fate.